Montelukast induced acute hepatocellular liver injury.
A 46-year-old male with uncontrolled asthma on inhaled albuterol and formoterol with budesonide was commenced on montelukast. He developed abdominal pain and jaundice 48 days after initiating montelukast therapy. His liver tests showed an increase in serum total bilirubin, conjugated bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase. The patient was evaluated for possible non-drug related liver injury. Montelukast was discontinued suspecting montelukast induced hepatocellular liver injury. Liver tests began to improve and returned to normal 55 days after drug cessation. Causality of this adverse drug reaction by the Council for International Organizations of Medical Sciences or Roussel Uclaf Causality Assessment Method (CIOMS or RUCAM) and Naranjo's algorithm was 'probable'. Liver tests should be monitored in patients receiving montelukast and any early signs of liver injury should be investigated with a high index of suspicion for drug induced liver injury.
Harugeri
A
A
Department of Pharmacy Practice, JSS College of Pharmacy, Mysore, India.
Parthasarathi
G
G
Sharma
J
J
D'Souza
G A
GA
Ramesh
M
M
D000085:Acetates / Q000009:adverse effects*; D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D003521:Cyclopropanes; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000009:adverse effects*; D013440:Sulfides
D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; C093875:montelukast